Cure Mito Foundation, in collaboration with five of the industry’s prominent rare disease companies – PTC Therapeutics, Inc., Astellas Pharma US, Saol Therapeutics, Standigm, and Abliva AB, today announced the launch of a unique Corporate Advisory Council (CAC).
Please learn more in the press release:
https://www.eurekalert.org/news-releases/976914
